Floodgates for cheap weight-loss drugs open as key patent expires

Delhi (TIP): The market for diabetes and weight-loss drugs is set for a transformation starting Friday as Danish drugmaker Novo Nordisk’s patent on semaglutide expires, triggering the launch of a multitude of cheaper generic versions.
More than 50 branded versions of semaglutide, the active ingredient in Novo’s diabetes drug Ozempic and weight-loss treatment Wegovy are expected to enter the Indian market, making it one of the most crowded drug launches in recent years. The influx is likely to sharply reduce prices and improve access for diabetes and obesity patients, but experts warn it could also lead to misuse. Sun Pharma, Mankind Pharma, Dr. Reddy’s , Zydus, Lupin and Alkem are among the companies expected to launch generic versions.
According to industry estimates, the new versions are likely to be priced at a third to a fifth of the innovator drug, bringing the monthly cost of the once a week injectable down to around Rs 3,000 to Rs 4,000. At present, Ozempic costs between Rs 8,800 and Rs 11,175 per month, while Wegovy ranges from Rs 10,850 to Rs 16,400, depending on dosage.
“Diabetes and obesity management is long term and expensive, so cheaper options will help families and improve adherence. It can also help doctors start treatment earlier,” said Dr Sandeep Kharb, senior consultant, endocrinology, Asian Hospital.However, experts caution that increased access may also lead to inappropriate use. “These drugs have already been widely promoted and used for weight loss without prescription. With cheaper options entering the market, misuse may increase if not regulated,” said Dr Vivek Bindal, senior director at Max Healthcare, adding that there is a need to prevent promotion for cosmetic use and improve public awareness.
Adding to this, Dr Saptarshi Bhattacharya, senior consultant, endocrinology, Indraprastha Apollo Hospitals, said the patent expiry marks a significant shift in chronic disease management. “Improved affordability and wider availability of generics will allow many more people, especially outside metro cities, to access a therapy that has proven benefits in blood glucose control and weight management.